[1]
Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Zoledronate. Bone. 2020 Aug:137():115390. doi: 10.1016/j.bone.2020.115390. Epub 2020 Apr 27
[PubMed PMID: 32353565]
[2]
Qaseem A, Forciea MA, McLean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians, Barry MJ, Cooke M, Fitterman N, Harris RP, Humphrey LL, Kansagara D, McLean RM, Mir TP, Schünemann HJ. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Annals of internal medicine. 2017 Jun 6:166(11):818-839. doi: 10.7326/M15-1361. Epub 2017 May 9
[PubMed PMID: 28492856]
Level 1 (high-level) evidence
[3]
Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nature reviews. Endocrinology. 2020 Aug:16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14
[PubMed PMID: 32286516]
[4]
Kravets I. Paget's Disease of Bone: Diagnosis and Treatment. The American journal of medicine. 2018 Nov:131(11):1298-1303. doi: 10.1016/j.amjmed.2018.04.028. Epub 2018 May 10
[PubMed PMID: 29752905]
[5]
Chakhtoura M, El-Hajj Fuleihan G. Treatment of Hypercalcemia of Malignancy. Endocrinology and metabolism clinics of North America. 2021 Dec:50(4):781-792. doi: 10.1016/j.ecl.2021.08.002. Epub
[PubMed PMID: 34774248]
[6]
Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 10:36(8):812-818. doi: 10.1200/JCO.2017.76.6402. Epub 2018 Jan 17
[PubMed PMID: 29341831]
Level 1 (high-level) evidence
[7]
von Moos R, Sternberg C, Body JJ, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2013 Jun:21(6):1773-83. doi: 10.1007/s00520-013-1755-1. Epub 2013 Mar 7
[PubMed PMID: 23468364]
[8]
El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2023 Feb 15:108(3):507-528. doi: 10.1210/clinem/dgac621. Epub
[PubMed PMID: 36545746]
Level 1 (high-level) evidence
[9]
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May:26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. Epub
[PubMed PMID: 32427503]
Level 1 (high-level) evidence
[10]
Pineda-Moncusí M, Garcia-Giralt N, Diez-Perez A, Servitja S, Tusquets I, Prieto-Alhambra D, Nogués X. Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 Feb:35(2):291-297. doi: 10.1002/jbmr.3886. Epub 2019 Oct 31
[PubMed PMID: 31596961]
[11]
Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. The Journal of urology. 2007 Jan:177(1):17-24
[PubMed PMID: 17161994]
[12]
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Mar 1:40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18
[PubMed PMID: 35041467]
[13]
Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). The Journal of urology. 2023 Jun:209(6):1082-1090. doi: 10.1097/JU.0000000000003452. Epub 2023 Apr 25
[PubMed PMID: 37096583]
[14]
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic proceedings. 2008 Sep:83(9):1032-45. doi: 10.4065/83.9.1032. Epub
[PubMed PMID: 18775204]
[15]
Shiraki M, Tanaka S, Suzuki H, Ueda S, Nakamura T. Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. Journal of bone and mineral metabolism. 2017 Nov:35(6):675-684. doi: 10.1007/s00774-016-0806-3. Epub 2016 Dec 20
[PubMed PMID: 28000034]
[16]
Bowden SA, Mahan JD. Zoledronic acid in pediatric metabolic bone disorders. Translational pediatrics. 2017 Oct:6(4):256-268. doi: 10.21037/tp.2017.09.10. Epub
[PubMed PMID: 29184807]
[18]
Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women. Clinical interventions in aging. 2008:3(3):445-51
[PubMed PMID: 18982915]
[19]
Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Dec 10:35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16
[PubMed PMID: 29035643]
[20]
Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 May 20:38(15):1736-1743. doi: 10.1200/JCO.19.03148. Epub 2020 Jan 28
[PubMed PMID: 31990618]
[21]
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Nov 1:37(31):2916-2946. doi: 10.1200/JCO.19.01696. Epub 2019 Sep 18
[PubMed PMID: 31532726]
Level 1 (high-level) evidence
[22]
Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2013 Oct:28(10):2049-59. doi: 10.1002/jbmr.2058. Epub
[PubMed PMID: 23907861]
[24]
Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011 Jul:49(1):103-10. doi: 10.1016/j.bone.2011.01.003. Epub 2011 Jan 12
[PubMed PMID: 21236370]
[25]
Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens, Greece). 2009 Apr-Jun:8(2):96-110
[PubMed PMID: 19570737]
[26]
Chen FP, Fu TS, Lin YC, Lin YJ. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2021 Apr:32(4):663-670. doi: 10.1007/s00198-020-05653-0. Epub 2020 Oct 28
[PubMed PMID: 33113007]
[27]
Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Jan:18(1):201-202. doi: 10.1093/annonc/mdl298. Epub 2006 Oct 4
[PubMed PMID: 17021272]
[28]
Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. The Journal of clinical endocrinology and metabolism. 2010 Sep:95(9):4380-7. doi: 10.1210/jc.2010-0597. Epub 2010 Jun 16
[PubMed PMID: 20554708]
[29]
Rudran B, Super J, Jandoo R, Babu V, Nathan S, Ibrahim E, Wiik AV. Current concepts in the management of bisphosphonate associated atypical femoral fractures. World journal of orthopedics. 2021 Sep 18:12(9):660-671. doi: 10.5312/wjo.v12.i9.660. Epub 2021 Sep 18
[PubMed PMID: 34631450]
[30]
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2014 Jan:29(1):1-23. doi: 10.1002/jbmr.1998. Epub 2013 Oct 1
[PubMed PMID: 23712442]
[31]
Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PloS one. 2015:10(4):e0122646. doi: 10.1371/journal.pone.0122646. Epub 2015 Apr 17
[PubMed PMID: 25884398]
Level 1 (high-level) evidence
[32]
Hirschberg R. Renal complications from bisphosphonate treatment. Current opinion in supportive and palliative care. 2012 Sep:6(3):342-7. doi: 10.1097/SPC.0b013e328356062e. Epub
[PubMed PMID: 22710581]
Level 3 (low-level) evidence
[33]
Corsello SM, Paragliola RM, Locantore P, Ingraudo F, Ricciato MP, Rota CA, Senes P, Pontecorvi A. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid. Hormones (Athens, Greece). 2010 Oct-Dec:9(4):338-42
[PubMed PMID: 21112866]
[34]
Roughead EE, Kerr M, Moffat A, Kassie GM, Pratt N. Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care. Drug safety. 2022 Nov:45(11):1413-1421. doi: 10.1007/s40264-022-01238-4. Epub 2022 Sep 21
[PubMed PMID: 36127547]
Level 2 (mid-level) evidence
[35]
Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. The Annals of pharmacotherapy. 2005 Jul-Aug:39(7-8):1194-7
[PubMed PMID: 15956222]
[36]
Rizzoli R, Reginster JY, Boonen S, Bréart G, Diez-Perez A, Felsenberg D, Kaufman JM, Kanis JA, Cooper C. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcified tissue international. 2011 Aug:89(2):91-104. doi: 10.1007/s00223-011-9499-8. Epub 2011 Jun 3
[PubMed PMID: 21637997]
[37]
Wu Q, Wang X, Nepovimova E, Wang Y, Yang H, Kuca K. Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2018 Aug:118():889-907. doi: 10.1016/j.fct.2018.06.054. Epub 2018 Jun 28
[PubMed PMID: 29960018]
[38]
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. The New England journal of medicine. 2007 Nov 1:357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17
[PubMed PMID: 17878149]
[39]
Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, Sawamura M, Yagi Y, Sasaki T, Takashima S. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Japanese journal of clinical oncology. 2005 Jan:35(1):28-33
[PubMed PMID: 15681601]
[40]
Khalafallah AA, Slancar M, Cosolo W, Abdi E, Chern B, Woodfield RJ, Copeman MC. Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study. European journal of cancer care. 2018 Mar:27(2):e12638. doi: 10.1111/ecc.12638. Epub 2017 Jan 30
[PubMed PMID: 28134499]
[41]
Nassar K, Janani S. Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report : Eruptions cutanées diffuses induites par l'administration de l'acide zolédronique. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2021 Dec:32(12):2583-2586. doi: 10.1007/s00198-021-06021-2. Epub 2021 Jun 3
[PubMed PMID: 34085118]
Level 3 (low-level) evidence
[42]
Teysseire R, Brochard P, Sentilhes L, Delva F. Identification and Prioritization of Environmental Reproductive Hazards: A First Step in Establishing Environmental Perinatal Care. International journal of environmental research and public health. 2019 Jan 28:16(3):. doi: 10.3390/ijerph16030366. Epub 2019 Jan 28
[PubMed PMID: 30696096]
[43]
Lorentzon M, Branco J, Brandi ML, Bruyère O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S, Gasparik A, Herrmann M, Jorgensen NR, Kanis J, Kaufman JM, Laslop A, Locquet M, Matijevic R, McCloskey E, Minisola S, Pikner R, Reginster JY, Rizzoli R, Szulc P, Vlaskovska M, Cavalier E. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in therapy. 2019 Oct:36(10):2811-2824. doi: 10.1007/s12325-019-01063-9. Epub 2019 Aug 22
[PubMed PMID: 31440982]
Level 3 (low-level) evidence
[44]
. 2022 ACMT Annual Scientific Meeting Abstracts - Virtual. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2022 Mar 2:18(2):75-125. doi: 10.1007/s13181-022-00888-1. Epub 2022 Mar 2
[PubMed PMID: 35235161]
[45]
Fan W, Machado M, Leder BZ, Beyer L, Garcia EF, Kronenberg HM, Cevallos S, Espinoza J, Finkelstein JS, Bolster MB. Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates. The Journal of clinical endocrinology and metabolism. 2022 Dec 17:108(1):191-197. doi: 10.1210/clinem/dgac508. Epub
[PubMed PMID: 36056816]